The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/1 - 1/1000.
Use a concentration of 10 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Probable E3 ubiquitin-protein ligase. The BRCA1-BARD1 heterodimer specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Plays a central role in the control of the cell cycle in response to DNA damage. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Also forms a heterodimer with CSTF1/CSTF-50 to modulate mRNA processing and RNAP II stability by inhibiting pre-mRNA 3' cleavage.
Processed during apoptosis. The homodimer is more susceptible to proteolytic cleavage than the BARD1/BRCA1 heterodimer.
Nucleus. During S phase of the cell cycle, colocalizes with BRCA1 into discrete subnuclear foci. Can translocate to the cytoplasm. Localizes at sites of DNA damage at double-strand breaks (DSBs); recruitment to DNA damage sites is mediated by the BRCA1-A complex.
ab115477, at 10µg/ml, staining BARD1 in formalin-fixed, paraffin-embedded Human skeletal muscle tissue by Immunohistochemistry, using a biotinylated anti-rabbit IgG secondary antibody, alkaline phosphatase-streptavidin and chromogen.
ab115477, at 10µg/ml, staining BARD1 in formalin-fixed, paraffin-embedded Human skin tissue by Immunohistochemistry, using a biotinylated anti-rabbit IgG secondary antibody, alkaline phosphatase-streptavidin and chromogen.